Early diagnosis of Alzheimer’s disease may now be possible well before severe cognitive symptoms appear, with the help of a new blood-based biomarker test combined with advanced imaging, a diagnostic centre chain said on Monday.
Mahajan Imaging and Labs has introduced an Artificial Intelligence-integrated blood biomarker test, supported by structured PET and MRI imaging pathways, marking a shift from symptom-led evaluations to a biology-first approach in Alzheimer’s diagnosis in India, according to media reports.
The diagnostic method uses the pTAU/Aβ1-42 blood biomarker test, which has received approval from both the US Food and Drug Administration and India’s Central Drugs Standard Control Organisation.
The expanded diagnostic pathway was formally unveiled and deliberated upon at a scientific symposium held in Gurugram on Sunday. Globally, Alzheimer’s diagnosis is increasingly reliant on amyloid PET imaging and cerebrospinal fluid (CSF) testing.
Also Read